Background/Objectives: For locally applied, locally acting generic drug products, comparison to an originator product based on systemic exposure is usually not feasible due to low plasma concentrations and inadequate reflection of local exposure at the site of action. Where a validated PD model exists, a comparative clinical study can be performed in healthy subjects; where no surrogate endpoint is available, patients with the relevant indication need to be enrolled, with all the associated factors which could result in lack of sensitivity. Even though the need for alternative in vitro approaches has been acknowledged by both industry and regulatory bodies, the complexity of in vivo drug delivery processes makes the development of guidance documents particularly difficult. Our objective was to present in vitro approaches less classically used and to address in vivo relevance of the selected tests. Methods: This article analyses current regulatory approaches in Europe and the U.S., and highlights the key advantages of in vitro tests in terms of their sensitivity, reliability, reproducibility and in vivo relevance using locally applied flurbiprofen in various formulations. Results: The in vitro esophageal retention (IVOR) model demonstrates that the first 6-10 min after application of different flurbiprofen formulations is important for their comparison and also offers the best correlation with in vivo data using the partial area under the concentration-time curves (pAUCs). Rheological evaluations further demonstrated that the mucoadhesive properties of the gel spray formulation are based on interaction with mucin. Conclusions: Designing a relevant in vitro test requires adequate evaluation of the complexity of the drug substance, drug product, dosing conditions and delivery processes.

Institute of Pharmacology 1st Faculty of Medicine Charles University Albertov 4 128 00 Prague Czech Republic

Reckitt Healthcare Limited 103 105 Bath Road Slough SL1 3UH UK

SAS BORVO 18 Av de Charade 63122 Ceyrat France

Zobrazit více v PubMed

EMA Guideline on Equivalence Studies for the Demonstration of Therapeutic Equivalence for Locally Applied, Locally Acting Products in the Gastrointestinal Tract: CPMP/EWP/239/95 Rev. 1, Corr.1*. [(accessed on 4 January 2024)]. Available online: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-equivalence-studies-demonstration-therapeutic-equivalence-locally-applied-locally-acting_en.pdf.

EMA Clinical Pharmacology and Pharmacokinetics: Questions and Answers. [(accessed on 4 January 2024)]. Available online: https://www.ema.europa.eu/en/human-regulatory-overview/research-and-development/scientific-guidelines/clinical-pharmacology-and-pharmacokinetics/clinical-pharmacology-and-pharmacokinetics-questions-and-answers.

FDA Product-Specific Guidances for Generic Drug Development. [(accessed on 4 January 2024)]; Available online: https://www.accessdata.fda.gov/scripts/cder/psg/index.cfm.

FDA Draft Guidance on Chlorhexidine Gluconate. [(accessed on 4 January 2024)]; Available online: https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020774.pdf.

FDA Applications Covered by Section 505(b)(2) [(accessed on 4 January 2024)]; Available online: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/applications-covered-section-505b2.

Code of Federal Regulation 21-CRF-320.24: Types of Evidence to Measure Bioavailability or Establish Bioequivalence. [(accessed on 4 January 2024)]; Available online: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-320/subpart-B/section-320.24.

EMA Guideline on the Investigation of Bioequivalence: CPMP/EWP/QWP/1401/98 Rev. 1/Corr** 2010. [(accessed on 4 January 2024)]. Available online: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-bioequivalence-rev1_en.pdf.

Cardot J.M., Savania N., Targett D., Freeman B., Gray H., Stahl T., Kästner U., Kulasekaran A. Validated correlation of in vitro and healthy subjects mass loss and drug release of sugared and sugar free cetylpyridinium chloride (CPC) and benzocaine (1.4 mg/10 mg) lozenges versus in vitro mass loss and corresponding drug release as a surrogate for local bioequivalence. J. Drug Deliv. Sci. Technol. 2022;77:103822. doi: 10.1016/j.jddst.2022.103822. DOI

EMA Draft Guideline on Quality and Equivalence of Topical Products: CHMP/QWP/708282/2018. [(accessed on 4 January 2024)]. Available online: https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-quality-and-equivalence-topical-products_en.pdf.

ICH Biopharmaceutics Classification System-Based Biowaivers M9. [(accessed on 4 January 2024)]. Available online: https://database.ich.org/sites/default/files/M9_Guideline_Step4_2019_1116.pdf.

Perlik V., Kulasekaran A., Coutinho G., Votava M., Cardot J.M. Relationship between Pharmacokinetic Profile and Clinical Efficacy Data of Three Different Forms of Locally Applied Flurbiprofen in the Mouth/Throat. Pharmaceutics. 2023;15:1863. doi: 10.3390/pharmaceutics15071863. PubMed DOI PMC

Turner R., Wevrett S.R., Edmunds S., Brown M.B., Atkinson R., Adegoke O., Kulasekaran A., Shea T. Determination of the Permeation and Penetration of Flurbiprofen into Cadaveric Human Pharynx Tissue. Clin. Pharmacol. 2020;12:13–20. doi: 10.2147/CPAA.S234227. PubMed DOI PMC

Turner R., Wevrett S.R., Edmunds S., Brown M., Kulasekaran A., Adegoke O., Farrah J. Penetration of Flurbiprofen from a Locally Applied Sore Throat Lozenge and Spray into Cadaveric Human Pharynx Tissue: A Novel ex vivo Model and Microautoradiography Method. Clin. Pharmacol. 2021;13:13–20. doi: 10.2147/CPAA.S284433. PubMed DOI PMC

Strefen Honey and Lemon, SmPC. [(accessed on 4 January 2024)]. Available online: https://www.medicines.org.uk/emc/product/6514/smpc.

Strefen Direct Cherry and Mint Flavour 8.75 mg Oromucosal Spray, SmPC. [(accessed on 4 January 2024)]. Available online: https://www.medicines.org.uk/emc/product/15868/smpc.

Gittings S., Turnbull N., Henry B., Roberts C.J., Gershkovich P. Characterisation of human saliva as a platform for oral dissolution medium development. Eur. J. Pharm. Biopharm. 2015;91:16–24. doi: 10.1016/j.ejpb.2015.01.007. PubMed DOI

Morjaria Y., Irwin W.J., Barnett P.X., Chan R.S., Conway B. In Vitro Release of Nicotine from Chewing Gum Formulations. Dissolution Technol. 2004;11:12–15. doi: 10.14227/DT110204P12. DOI

Humphrey S.P., Williamson R.T. A review of saliva: Normal composition, flow, and function. J. Prosthet. Dent. 2001;85:162–169. doi: 10.1067/mpr.2001.113778. PubMed DOI

Young S.A., Smart J.D. A novel in-vitro apparatus for evaluating the mucoadhesion of liquid and semi-solid formulations. J. Pharm. Pharmacol. 1998;50((Suppl. 9)):167. doi: 10.1111/j.2042-7158.1998.tb02367.x. PubMed DOI

Turner R., Wevrett S.R., Edmunds S., Brown M., Atkinson R., Shea T. Validation of an analytical method to quantify the permeation and penetration of flurbiprofen into human pharynx tissue. Biomed. Chromatogr. 2019;33:e4499. doi: 10.1002/bmc.4499. PubMed DOI PMC

EMA Guideline on the Requirements for Clinical Documentation for Orally Inhaled Products (Oip) Including the Requirements for Demonstration of Therapeutic Equivalence between Two Inhaled Products for Use in the Treatment of Asthma and Chronic Obstructive Pulmonary Disease (Copd) in Adults and for Use in the Treatment of Asthma in Children and Adolescents: CPMP/EWP/4151/00 Rev. 1. 2009. [(accessed on 4 January 2024)]. Available online: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-requirements-clinical-documentation-orally-inhaled-products-including-requirements-demonstration-therapeutic-equivalence-between-two-inhaled-products-use-treatment-asthma-and-chronic_en.pdf.

García-Arieta A. A European perspective on orally inhaled products: In vitro requirements for a biowaiver. J. Aerosol. Med. Pulm. Drug Deliv. 2014;27:419–429. doi: 10.1089/jamp.2014.1130. PubMed DOI

FDA Controlled Correspondence Related to Generic Drug Development. [(accessed on 4 January 2024)]; Available online: https://www.fda.gov/media/164111/download.

FDA Physicochemical and Structural (Q3) Characterization of Topical Drug Products Submitted in ANDAs. [(accessed on 4 January 2024)]; Available online: https://www.fda.gov/media/162471/download.

FDA In Vitro Release Test Studies for Topical Drug Products Submitted in ANDAs. [(accessed on 4 January 2024)]; Available online: https://www.fda.gov/media/162476/download.

FDA In Vitro Permeation Test Studies for Topical Drug Products Submitted in ANDAs. [(accessed on 4 January 2024)]; Available online: https://www.fda.gov/media/162475/download.

FDA Topical Dermatologic Corticosteroids: In Vivo Bioequivalence. [(accessed on 4 January 2024)]; Available online: https://www.fda.gov/media/162457/download.

Madsen F., Eberth K., Smart J.D. A rheological examination of the mucoadhesive/mucus interaction: The effect of mucoadhesive type and concentration. J. Control Release. 1998;50:167–178. doi: 10.1016/S0168-3659(97)00138-7. PubMed DOI

Burova N., Bychkova V., Shephard A. Improvements in throat function and qualities of sore throat from locally applied flurbiprofen 8.75 mg in spray or lozenge format: Findings from a randomized trial of patients with upper respiratory tract infection in the Russian Federation. J. Pain Res. 2018;11:1045–1055. doi: 10.2147/JPR.S149331. PubMed DOI PMC

Radkova E., Burova N., Bychkova V., DeVito R. Efficacy of flurbiprofen 8.75 mg delivered as a spray or lozenge in patients with sore throat due to upper respiratory tract infection: A randomized, non-inferiority trial in the Russian Federation. J. Pain Res. 2017;10:1591–1600. doi: 10.2147/JPR.S135602. PubMed DOI PMC

Voltarol 1.16% Emulgel, gel, SmPC. [(accessed on 4 January 2024)]. Available online: https://www.medicines.org.uk/emc/product/366/smpc#about-medicine.

EMA Guideline on the Pharmaceutical Quality of Inhalation and Nasal Products: EMEA/CHMP/QWP/49313/2005 Corr. [(accessed on 4 January 2024)]. Available online: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-pharmaceutical-quality-inhalation-and-nasal-products_en.pdf.

FDA Nasal Spray and Inhalation Solution, Suspension, and Spray Drug Products—Chemistry, Manufacturing, and Controls Documentation. [(accessed on 4 January 2024)]; Available online: https://www.fda.gov/files/drugs/published/Nasal-Spray-and-Inhalation-Solution--Suspension--and-Drug-Products.pdf.

USP Chapter <601> Inhalation and Nasal Drug Products: Aerosols, Sprays, and Powders—Performance Quality Test. [(accessed on 4 January 2024)]. Available online: https://doi.usp.org/USPNF/USPNF_M99360_05_01.html.

Ph.Eur. Monograph 0676. 11th Edition, 2023. [(accessed on 4 January 2024)]. Available online: https://www.edqm.eu/en/european-pharmacopoeia-ph.-eur.-11th-edition.